JP2024506942A5 - - Google Patents

Info

Publication number
JP2024506942A5
JP2024506942A5 JP2023549823A JP2023549823A JP2024506942A5 JP 2024506942 A5 JP2024506942 A5 JP 2024506942A5 JP 2023549823 A JP2023549823 A JP 2023549823A JP 2023549823 A JP2023549823 A JP 2023549823A JP 2024506942 A5 JP2024506942 A5 JP 2024506942A5
Authority
JP
Japan
Prior art keywords
citrate
hemy
compound
pharmaceutical composition
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023549823A
Other languages
English (en)
Japanese (ja)
Other versions
JP7874887B2 (ja
JP2024506942A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/016612 external-priority patent/WO2022178000A1/en
Publication of JP2024506942A publication Critical patent/JP2024506942A/ja
Publication of JP2024506942A5 publication Critical patent/JP2024506942A5/ja
Priority to JP2026025898A priority Critical patent/JP2026097871A/ja
Application granted granted Critical
Publication of JP7874887B2 publication Critical patent/JP7874887B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023549823A 2021-02-18 2022-02-16 Gaba-aポジティブアロステリック調節物質のヘミ-クエン酸塩およびその結晶形態 Active JP7874887B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026025898A JP2026097871A (ja) 2021-02-18 2026-02-20 Gaba-aポジティブアロステリック調節物質のヘミ-クエン酸塩およびその結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150782P 2021-02-18 2021-02-18
US63/150,782 2021-02-18
PCT/US2022/016612 WO2022178000A1 (en) 2021-02-18 2022-02-16 Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026025898A Division JP2026097871A (ja) 2021-02-18 2026-02-20 Gaba-aポジティブアロステリック調節物質のヘミ-クエン酸塩およびその結晶形態

Publications (3)

Publication Number Publication Date
JP2024506942A JP2024506942A (ja) 2024-02-15
JP2024506942A5 true JP2024506942A5 (cg-RX-API-DMAC10.html) 2025-02-25
JP7874887B2 JP7874887B2 (ja) 2026-06-17

Family

ID=82931143

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023549823A Active JP7874887B2 (ja) 2021-02-18 2022-02-16 Gaba-aポジティブアロステリック調節物質のヘミ-クエン酸塩およびその結晶形態
JP2026025898A Pending JP2026097871A (ja) 2021-02-18 2026-02-20 Gaba-aポジティブアロステリック調節物質のヘミ-クエン酸塩およびその結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026025898A Pending JP2026097871A (ja) 2021-02-18 2026-02-20 Gaba-aポジティブアロステリック調節物質のヘミ-クエン酸塩およびその結晶形態

Country Status (5)

Country Link
US (2) US20240190910A1 (cg-RX-API-DMAC10.html)
EP (1) EP4294819A4 (cg-RX-API-DMAC10.html)
JP (2) JP7874887B2 (cg-RX-API-DMAC10.html)
TW (1) TW202245790A (cg-RX-API-DMAC10.html)
WO (1) WO2022178000A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
EP4514357A4 (en) * 2022-04-26 2026-04-29 Praxis Prec Medicines Inc METHODS OF TREATING NEUROLOGICAL DISORDERS

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
DK2168585T3 (da) * 2005-06-09 2012-02-27 Euro Celtique Sa Farmaceutiske sammensætninger af en neuroaktiv steroid og anvendelser deraf
US10562930B1 (en) * 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator

Similar Documents

Publication Publication Date Title
US20200283419A1 (en) Polymorphs of selinexor
JP2024178291A (ja) (r)-2-アミノ-3-フェニルプロピルカルバメートの溶媒和物フォーム
TW201408661A (zh) 抗病毒性化合物之固體形式
BRPI0616801B1 (pt) Forma polimórfica de 5-cloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morfolinil)-fenil]-1,3-oxazolidin-5-il}-metil)-2-tiofenocarboxamida, seus processos de preparação e seus usos, medicamento, e processo para prevenção de coagulação de sangue in vitro
TW200827326A (en) Organic compounds
TW200924786A (en) Certain compounds, compositions and methods
TWI333419B (en) Crystalline sodium salt, process for the manufacture thereof and use thereof for the preparation of a medicament
CN111328280A (zh) 制备和使用内昔芬的方法
JP2023103328A (ja) ビランテロールトリフェニル酢酸塩の新規な結晶形態及びこれらの調製プロセス
CN105189513A (zh) 葡萄糖醇,1-脱氧-1-(甲胺基)-,1-(6-氨基-3,5-二氟吡啶-2-基)-8-氯-6-氟-1,4-二氢-7-(3-羟基氮杂环丁烷-l-基)-4-氧-3-喹啉羧酸盐的结晶形态
JP2023523770A5 (cg-RX-API-DMAC10.html)
CN103833712B (zh) 硝克柳胺化合物晶ii型、其制法和其药物组合物与用途
JP2014051517A (ja) デフェラシロックス(icl670a)の多形形態
JP2020073513A (ja) α,ω‐二置換ジヒドロキシシクロペンチル化合物の固体形態、並びにその製造及び使用方法
JP2000514096A (ja) 炭素環式ヌクレオシドヘミスルフェートおよびウイルス感染症の治療におけるその使用
JP7854206B2 (ja) 肺線維症の予防または治療用の薬学製剤
US20080234323A1 (en) Amorphous and Three Crystalline Forms of Rimonabant Hydrochloride
CN101282968B (zh) 多晶态形式和非晶态形式的5-氯-n-({(5s)-2-氧-3-[4-(3-氧-4-吗啉基)-苯基]-1,3-*唑烷-5-基}-甲基)-2-噻吩羧酰胺
CN102282125A (zh) 新方法和纯的多晶型物
CN1214029C (zh) 4-氨基-6,7-二甲氧基-2-(5-甲磺酰氨基-1,2,3,4-四氢异喹啉-2-基)-5-(2-吡啶基)喹唑啉甲磺酸盐及多晶形物
JP5888612B2 (ja) 縮合ピリジン化合物塩の結晶
CN103068392A (zh) 苯甲酸阿格列汀的多晶形物
CN102190656A (zh) 含有五元杂环的噁唑烷酮抗菌素
CN107056819B (zh) 一种预防和治疗心肌缺血的药物及其制备方法
JP2018537469A5 (cg-RX-API-DMAC10.html)